ReviewCancer management and research2025
Research on Buyang Yiwei Decoction in the Treatment of Gastric Cancer Based on PI3K/AKT Signaling Pathway: A Review.
Review in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer is a digestive tract malignant tumor with high incidence and high mortality rate in the world, and patients with advanced gastric cancer often face clinical difficulties such as drug resistance and significant toxic and side effects. Traditional Chinese medicine shows unique advantages of multi-target and multi-pathway regulation in the comprehensive treatment of gastric cancer. Buyang Yiwei Decoction is a classic prescription for replenishing qi and nourishing blood, and combining tonification with dispersion. Clinical studies have confirmed that Buyang Yiwei Decoction combined with chemotherapy can significantly improve the performance status of patients with advanced gastric cancer, decrease the levels of tumor markers, and alleviate chemotherapy-induced organ damage/toxicities. In this paper, we systematically combed the key biological processes of the PI3K/AKT signaling pathway in the occurrence and development of gastric cancer. Our study found that the core active ingredients of Buyang Yiwei Decoction have been shown to inhibit the abnormal activation of the PI3K/AKT pathway, down-regulate the key phosphorylated proteins in this pathway, regulate downstream effector molecules, and thereby exert the molecular mechanism of inhibiting gastric cancer cell proliferation, inducing apoptosis, suppressing invasion and metastasis, and reversing chemotherapy resistance. However, current studies on the holistic mechanism of Buyang Yiwei Decoction remain insufficient; the evidence for clinical translation is weak; and the precision of its therapeutic targets needs to be improved. The next step is to further elucidate the multi-component synergistic mechanisms by which Buyang Yiwei Decoction regulates the PI3K/AKT pathway through an integrated approach combining network pharmacology, animal model validation, and multi-center clinical research. It is also essential to clarify its precise therapeutic value in targeting specific pathological processes. This will provide a more targeted, mechanism-elucidated, and higher-level evidence-based scientific foundation for its clinical application as an adjunctive strategy in the precision treatment of gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.